In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

The patent expiry of key drugs in 2025-26 will open up additional market space for Indian manufacturers of generics and ...

Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...

Union Finance Minister Nirmala Sitharaman is all set to present her eighth budget on February 1. Tax simplification, ...

Kiran Mazumdar-Shaw, Chairperson of major drugmaker Biocon Ltd., urged the government to eliminate tax on drugs for cancer treatment and for chronic and rare diseases, ahead of the budget 2025 ...

Clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1% triple-combination topical surpassed dyad formulations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The novelist is 75. Rusty Sabich, the now-retired prosecutor he introduced in “Presumed Innocent,” is 77 — and taking on a new case in “Presumed Guilty.” By Sarah Lyall In “Bright ...

Divis Labs has been an outperformer in the pharma pack so far in this series, as most of the pharma stocks have corrected in the January series, apart from a few like Divis Labs and Biocon.

Hence, we recommend buying Reliance Industries around Rs 1,290. Biocon is reflecting strong volumes over the past week, indicating growing investor interest. The stock is approaching a critical ...

Examining what it means to make money by selling the bereaved on an illusion, the film feels like something of a warning. By Alissa Wilkinson Mel Gibson directs an uneven action film with Mark ...

Join former prosecutor Andy McCarthy as he delves into the legal ins and outs of the latest Washington dramas with National Review editor in chief Rich Lowry. Capital Record – your weekly ...